Paul Hastings Advised Jefferies LLC on Esperion Therapeutics’ $85.1 Million Public Offering
Paul Hastings LLP advised Jefferies LLC as sole book running manager in connection with Esperion Therapeutics, Inc.’s, (Nasdaq: ESPR) $85.1 million public offering of common stock. In addition, Esperion granted Jefferies a 30-day option to purchase additional shares of its common stock at the public offering price, less underwriting discounts and commissions. Esperion is a pharmaceutical company focused on discovering, developing and commercializing medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
Partner and co-head of Equity Capital Markets and co-chair of the Corporate Life Sciences Group Seo Salimi and Securities and Capital Markets partner Will Magioncalda led the Paul Hastings team, which also included Chris Guerin and Adam Swank.
More details about the transaction can be found here.
With widely recognized elite teams across 18 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world's leading investment banks, asset managers and corporations.